This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chung, Y.-L. Articles by Chi, K.-H. Search for Related Content PubMed PubMed Citation Articles by Chung, Y.-L. Articles by Chi, K.-H.

A Novel Approach for Nasopharyngeal Carcinoma Treatment Uses Phenylbutyrate as a Protein Kinase C Modulator: Implications for Radiosensitization and EBV-targeted Therapy¹

Cancer Center, Veterans General Hospital-Taipei, Taipei 11217, Taiwan, Republic of China [Y-L. C., S-H. Y., K-H. C.], and School of Medicine [Y-L. C., S-H. Y., K-H. C.] and Institute of Biochemistry, [Y-H. W. L.], National Yang-Ming University, Taipei, 11217 Taiwan, Republic of China

Sodium phenylbutyrate (NaPB) represent a new nontoxic class of compounds with antiproliferative activities to different tumors and has been shown to modulate many gene expressions by inhibiting histone deacetylation and DNA methylation as the major mechanism. Butyrate and other protein kinase C (PKC) activators have been reported to be able to activate virus enzymes. The present work investigates whether NaPB has an antiproliferative effect or modulatory effects on EBV-associated nasopharyngeal carcinoma (NPC) and whether EBV thymidine kinase gene can be activated to make cells susceptible to ganciclovir (GCV) therapy. NaPB treatment displayed a dose- and time-dependent antiproliferative effect on the NPC cell line CNE2. Cell cycle analysis revealed an inhibitory effect of NaPB on G₁-S-phase progression. Shortly after NaPB treatment, we found that PKC activity was activated rapidly but also decreased rapidly. Down-regulation of PKC- and translocation of PKC- from the cytosol to membrane were seen by Western blot. The decrease in PKC activity by NaPB corresponds to an enhanced response to radiation on CEN2 cells. Moreover, NaPB up-regulated EBV thymidine kinase activity to render EBV-associated Daudi cells susceptible to killing by GCV. Based on the observations of NaPB as a PKC modulator, the combination of NaPB, GCV, and radiation may provide a potential novel approach for treatment of EBV-associated NPC.

This article has been cited by other articles:

				A. Munshi, J. F. Kurland, T. Nishikawa, T. Tanaka, M. L. Hobbs, S. L. Tucker, S. Ismail, C. Stevens, and R. E. Meyn Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity Clin. Cancer Res., July 1, 2005; 11(13): 4912 - 4922. [Abstract] [Full Text] [PDF]

				S. Roychowdhury, R. Peng, R. A. Baiocchi, D. Bhatt, S. Vourganti, J. Grecula, N. Gupta, C. F. Eisenbeis, G. J. Nuovo, W. Yang, et al. Experimental Treatment of Epstein-Barr Virus-associated Primary Central Nervous System Lymphoma Cancer Res., March 1, 2003; 63(5): 965 - 971. [Abstract] [Full Text] [PDF]